Floatz logo

DEXAMETHASONE

Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

David Bond, MDSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type cohort.

Asset / SponsorPhaseRating
cc-5013
David Bond, MD
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Epirubicin
Mayo Clinic
Phase 2CCC
ETOPOSIDE
David Bond, MD
Phase 2CCC
Pembrolizumab
Mayo Clinic
Phase 2CCC

View all 12 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →